Disease-modifying Treatments and Cognition in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
Click HERE to Subscribe for the MS Beacon Newsletter Full report Abstract Objective: Disease-modifying treatments (DMTs) are the gold standard for…
FDA Approves Bafiertam, (a Tecfidera) Generic, for Relapsing MS
Banner Life Sciences Announces Final FDA Approval of BAFIERTAM for Multiple Sclerosis BAFIERTAM™ (monomethyl fumarate), the bioequivalent alternative to Biogen’s…
Stuart Schlossman
Siponimod Shows EDSS Subscale Benefits in Secondary Progressive MS
Novartis’s S1P receptor modulator siponimod (Mayzent) showed benefits in a number of patients with SPMS on the Motor Integration and…
Stuart Schlossman
The COVID-19 pandemic and the use of MS disease-modifying therapies
Maria was distraught after reading about the ‘potential’ epidemic, yet to happen, and the horror stories on Facebook needing reassurance…
Stuart Schlossman
OCREVUS® (ocrelizumab) Pregnancy Registry
OCREVUS® (ocrelizumab) Pregnancy Registry https://www.ocrevuspregnancyregistry.com/ Do you have multiple sclerosis (MS) and are you pregnant? Then you may be able…
Stuart Schlossman
Starting Mayzent Early of Greater Benefit in SPMS, 5-Year Trial Data Show
APRIL 22, 2020 – BY MARISA WEXLER, MS Click HERE to Subscribe for the MS Beacon Newsletter People with secondary progressive…
Stuart Schlossman
Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis
PRESS RELEASES April 23 2020 Click HERE to Subscribe for the MS Beacon Newsletter Sanofi brain-penetrant BTK inhibitor significantly…
Stuart Schlossman
Shorter Ocrelizumab Infusion Accepted for FDA Review
The FDA has accepted an sBLA for a version of Genentech’s ocrelizumab with a shorter administration time for the treatment…
Stuart Schlossman
Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S.
For those in US, P.R and US Virgin Islands Immediate Relief Available April 07, 2020 06:59 AM Eastern Daylight Time…
Stuart Schlossman
FDA Removes Pregnancy Category C Warning From Certain MS Medications
Clinical Neurology News/Neurology Reviews, By Lucas Franki April 2, 2020 https://www.mdedge.com/neurology/article/220153/multiple-sclerosis/fda-removes-pregnancy-category-c-warning-certain-ms The Food and Drug Administration has updated the labels…
Stuart Schlossman
